|Mr. Martin A. Lehr||Co-Founder, Pres, CEO & Director||523.71k||N/A||1984|
|Ms. Jennifer Minai-Azary||CFO & Treasurer||404.33k||N/A||1978|
|Mr. Alex C. Levit Esq.||Chief Legal Officer & Corp. Sec.||490.82k||N/A||1979|
|Dr. Felix Kim Ph.D.||Co-founder & Chair of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Christopher Beck M.B.A.||Sr. VP of Operations||N/A||N/A||N/A|
|Dr. Tarek Sahmoud M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1961|
|Dr. Evan G. Dick||Sr. VP of R&D||N/A||N/A||1952|
|Ms. Elizabeth Nemchik CPA||Controller||N/A||N/A||N/A|
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.